Know more unknowns

Diagnosis starts with casting the widest net possible. Conclusively capture and identify critical pathogens with a single, comprehensive, and unbiased metagenomic NGS-based test.

FEATURED NEWS
Delve’s Co-Founder Michael Wilson Featured on Encephalitis International podcast

Delve co-founder, Dr. Michael Wilson, joined Encephalitis International to discuss the difficulties in diagnosing encephalitis and how new technologies can help patients get answers faster.

home-img-2

Delve Neuro

Delve Neuro provides pathogen-agnostic and unbiased detection of neuro-infectious pathogens in cerebrospinal fluid (CSF) in one shot.

  • Samples the entire metagenomic content – DNA and RNA – within a patient sample.
  • Uses a proprietary mNGS bioinformatic pipeline to rapidly analyze millions of sequences.
  • Rapidly and accurately identifies bacterial, viral, fungal, and parasitic species.

Learn More

ucsf logo

As exclusive licensee of University of California San Francisco’s (UCSF) metagenomic sequencing (mNGS) technology, Delve Bio leverages mNGS to empower labs and clinicians with the results they need to diagnose routine and rare infectious diseases.

Meet the Delve Team

Leadership

Brad Murray, MBA

Founder & CEO

Emily Crawford, PhD

Head of R&D

Andrew Carretta

Director of Software Engineering

Coren Milbury, PhD

VP of Product Development and Leadership

Steve Miller

Steve Miller, MD, PhD

Chief Medical Officer

Jeff Field

Chief Commercial Officer

Amy Wong, PhD

Senior Director of Marketing and Business Development

Brian O’Donovan, PhD

Head of Bioinformatics

Founders

Michael Wilson, MD

Professor, University of California San Francisco
https://wilsonlab.ucsf.edu

Pardis Sabeti, MD, PhD

Professor, Harvard University
Institute Member, Broad Institute
https://www.sabetilab.org

Joe DeRisi, PhD

Professor, University of California San Francisco
President, Chan Zuckerberg Biohub
https://derisilab.ucsf.edu

Matthew Meyerson, MD, PhD

Director, Center for Cancer Genomics, Dana-Farber Cancer Institute
Professor of Genetics and Medicine, Harvard Medical School
Institute Member, Cancer Program, Broad Institute
https://meyersonlab.dana-farber.org

Charles Chiu, MD, PhD

Professor, Laboratory Medicine and Medicine / Infectious Diseases, University of California, San Francisco
Associate Director, UCSF Clinical Microbiology Laboratory
Investigator, Chan-Zuckerberg Biohub
https://chiulab.ucsf.edu

Board of Directors

Brad Murray, MBA

Founder & CEO

Michael Wilson, MD

Professor, University of California San Francisco
https://wilsonlab.ucsf.edu

Mike Pellini

Mike Pelini, MD

General Partner, S32

Chris Garabedian

Chris Garabedian

Portfolio Manager, Venture, Perceptive Advisors

Jay Wohlgemuth

Jay Wohlgemuth, MD

Managing Partner, Trusted Health Advisors

Investors

Xontogeny

Perceptive Xontogeny Venture Fund II

Section 32

Section 32

Google Ventures

Google Ventures

Publications

Clinical Metagenomic Sequencing for Diagnosis of Meningitis and Encephalitis.

The New England Journal of Medicine. 2019

Actionable Diagnosis of Neuroleptospirosis by Next-Generation Sequencing.

The New England Journal of Medicine. 2014

Rapid Pathogen Detection by Metagenomic Next-Generation Sequencing of Infected Body Fluids.

Nat Med. 2021

Clinical metagenomics.

Nature Reviews: Genetics. 2019

Metagenomics for neurological infections — expanding our imagination.

Nature Reviews: Neurology. 2020

A cloud-compatible bioinformatics pipeline for ultrarapid pathogen identification from next-generation sequencing of clinical samples.

Genome Research. 2014

Enhanced Virus Detection and Metagenomic Sequencing in Patients with Meningitis and Encephalitis.

American Society for Microbiology. 2021

Integrating central nervous system metagenomics and host response for diagnosis of tuberculosis meningitis and its mimics.

Nature Communications. 2022 

Unbiased Metagenomic Sequencing for Pediatric Meningitis in Bangladesh Reveals Neuroinvasive Chikungunya Virus Outbreak and Other Unrealized Pathogens

American Society for Microbiology. 2019

Metagenomic Next-Generation Sequencing for Diagnosis of Pediatric Meningitis and Encephalitis: A Review

Journal of the Pediatric Infectious Diseases Society. 2021

The Comparative Utility Of Metagenomic Next-Generation Sequencing and Universal PCR for Pathogen Detection on Cerebrospinal Fluid: A Retrospective Analysis From a Tertiary Care Center

Open Forum Infectious Diseases. 2019

Severe Neuroinvasive West Nile Virus in Association With Anti-CD20 Monotherapy for Multiple Sclerosis

Neurology Neuroimmunology & Neuroinflammation. 2023

Transmission of yellow fever vaccine virus through blood transfusion and organ transplantation in the USA in 2021: report of an investigation

The Lancet. 2023.

News and Updates

  • AMERICAN SOCIETY FOR MICROBIOLOGY

    Delve Founder Charles Chiu Receives ASM Award

    Delve Founder, Charles Chiu, M.D., Ph.D., receives 2023 ASM Research or Leadership in Clinical Microbiology Award. The ASM Award for Research or Leadership in Clinical Microbiology recognizes an outstanding scientist/clinical microbiologist with distinguished research achievements or a record of innovation and advancement of the clinical microbiology profession.

    AMERICAN SOCIETY FOR MICROBIOLOGY

  • WALL STREET JOURNAL

    Even a Brain-Eating Amoeba Can’t Hide From This Cutting-Edge Diagnosis Tech

    When a middle-aged man who had suffered a seizure was admitted to the University of California San Francisco Medical Center in 2021, doctors seeking the cause for his condition quickly became stumped.

    WALL STREET JOURNAL

  • TEDMED

    Combating Infectious Diseases With Next-Generation Sequencing

    Check out Charles’s 2016 TEDMED Talk to learn how next-gen sequencing is accelerating the process of diagnosing mysterious infectious diseases and helping doctors to deliver life-saving treatments.

    TEDMED

  • THE NEW YORK TIMES

    The Disease Detective

    Joe DeRisi invented a way to find pathogens that scientists didn’t even know to look for. Can it help prevent the next pandemic?

    THE NEW YORK TIMES

  • PREMONITION

    The Premonition: A Pandemic Story

    When a middle-aged man who had suffered a seizure was admitted to the University of California San Francisco Medical Center in 2021, doctors seeking the cause for his condition quickly became stumped.

    PREMONITION

  • THE NEW YORKER

    Inside the Ebola Wars

    How genomics research can help contain the outbreak.

    THE NEW YORKER

  • THE NEW YORK TIMES

    What if There Was Never a Pandemic Again?

    Modern humans have existed for over 200,000 years. A mere 500 years ago, daily life was ‌strewn with infectious risk. ‌Eating a meal was a risk, as was drinking a glass of water.

    THE NEW YORK TIMES

  • CDC

    Delve Partners at UCSF Team Up with CDC to Confirm First US Case in Fungal Meningitis Outbreak

    Delve partners at UCSF have collaborated with the US CDC to confirm the first positive case of Fusarium infection in a US patient following an outbreak of fungal meningitis stemming from epidural anesthesia in two Mexico clinics.

    CDC

  • BUSINESS WIRE

    Delve Bio Launches to Commercialize its Metagenomic Sequencing Platform for Infectious Disease Diagnosis

    Platform developed at the UCSF Center for Next-Gen Precision Diagnostics. $35M Series A financing led by Perceptive Xontogeny Venture Fund II. Funds will enable broader access to mNGS testing and the development of a pipeline of next-generation tests.

    BUSINESS WIRE

  • AMERICAN NEUROLOGICAL ASSOCIATION

    Delve founder, Dr. Michael Wilson, MD has been selected as the recipient of the 2023 ANA Awards for Excellence

    This award was established to recognize an individual who has made novel scientific contributions that reshape the field’s conceptual understanding of specific neurological syndromes or diseases, novel or sustained contributions through the development of new therapeutics for neurological diseases, and/or a major contribution that transforms or expands diagnostic tools in neurology.

    AMERICAN NEUROLOGICAL ASSOCIATION

  • UCSF MAGAZINE

    The Case of the Brain-Eating Amoeba

    After diagnosing a middle-aged man with an incredibly rare and almost always fatal infection, a medical team led by UCSF fellow Natasha Spottiswoode raced to find a treatment that could save his life.

    UCSF MAGAZINE

  • GENOME WEB

    Delve Bio Seeks to Commercialize UCSF Metagenomic Pathogen Test

    GENOME WEB

  • SCIENCE FRIDAY

    Delve founder, Dr. Joe DeRisi, interviewed on the latest episode of Science Friday podcast

    The latest episode of Science Friday features an interview with Delve Founder, Joe DeRisi, PhD, who discusses his work solving “medical mysteries” and how Delve can help treat patients with no clear explanation for their symptoms.

    SCIENCE FRIDAY

  • BIOSPACE

    Delve Bio was Named on the “NextGen Class of 2024: Top Life Sciences Startups to Watch This Year” List

    Delve Bio was assessed, nominated and voted by the BioSpace editorial team using several different criteria including finance, partnerships, pipeline, growth potential and innovation.

    BIOSPACE

  • SCIENCE

    Delve Founder’s Research Used to Treat Rare Brain-eating Amoeba Infection

    Delve founders, Drs. Joe DeRisi and Michael Wilson, led extensive research on potential treatments for Balamuthia infection, which a team at UCSF has now used to successfully treat a patient.

    SCIENCE

  • BUSINESS WIRE

    Delve Bio presents study showing utility of metagenomic next generation sequencing (mNGS) in diagnosing neurological infections

    Study presented as oral presentation at the 2024 Annual Meeting of the American Academy of Neurology.

    BUSINESS WIRE

  • BUSINESS WIRE

    Delve Bio Announces Clinical Data on the Use of Metagenomic Next-Generation Sequencing (mNGS) to Identify Pathogens Causing Central Nervous System Infections

    In a study of more than 4,800 patients over seven years, mNGS testing detected pathogens in nearly 15% of samples, encompassing more than 440 unique pathogen species

    BUSINESS WIRE